APP can be processed via various complex pathways to produce amyloidogenic and non-amyloidogenic peptides. In the ␣-secretase pathway, APP holoprotein is cleaved within the amyloidogenic A␤ domain producing a large N-terminal nonamyloidogenic soluble APP (sAPP␣), which is secreted in the extracellular medium (5). Secreted sAPP␣ has potent neurotrophic and neuroprotective activities by preventing oxidative damage induced by A␤ (6 -8). Alternatively, the so-called ␤-,␥-secretase pathway of APP leads to the formation of intact A␤ peptides that can form neurotoxic A␤ aggregates (9). Because of their role in the production of A␤, the molecular identification of APP secretases and the regulation of their cellular activity are under intense investigations. Recently, an aspartic protease, ␤-site APP-cleaving enzyme (named BACE), has been cloned and characterized for its ␤-secretase activity (for review see Ref. 10). Also, a number of ␤-and ␥-secretase inhibitors have been synthesized and successfully used to lower A␤ secretion (11-13). However, the ␤-and ␥-secretases may be implicated in the processing of other proteins having specific functions, and consequently the use of inhibitors may have unwanted side effects (14).
APP can be processed via various complex pathways to produce amyloidogenic and non-amyloidogenic peptides. In the ␣-secretase pathway, APP holoprotein is cleaved within the amyloidogenic A␤ domain producing a large N-terminal nonamyloidogenic soluble APP (sAPP␣), which is secreted in the extracellular medium (5) . Secreted sAPP␣ has potent neurotrophic and neuroprotective activities by preventing oxidative damage induced by A␤ (6 -8) . Alternatively, the so-called ␤-,␥-secretase pathway of APP leads to the formation of intact A␤ peptides that can form neurotoxic A␤ aggregates (9) . Because of their role in the production of A␤, the molecular identification of APP secretases and the regulation of their cellular activity are under intense investigations. Recently, an aspartic protease, ␤-site APP-cleaving enzyme (named BACE), has been cloned and characterized for its ␤-secretase activity (for review see Ref. 10) . Also, a number of ␤-and ␥-secretase inhibitors have been synthesized and successfully used to lower A␤ secretion (11) (12) (13) . However, the ␤-and ␥-secretases may be implicated in the processing of other proteins having specific functions, and consequently the use of inhibitors may have unwanted side effects (14) .
G-protein-coupled receptors (GPCRs) may regulate APP metabolism though a complex network of intracellular second messengers (Ref. 15 and for review see Ref. 16 ). These include phospholipase C-coupled receptors such as muscarinic acetylcholine m1 and m3 receptor subtypes and metabotropic glutamate receptors (16 -18) . More recently, the neuroprotective activity of the corticotropin-releasing hormone receptor type I, which is positively coupled to adenylate cyclase, has been shown to be accompanied by an increased release of sAPP␣ (19) . Many populations of neurons are affected in AD, especially the cholinergic and serotoninergic neurons of hippocampal and cortical regions. Because neuronal activity may be involved in the regulation of APP metabolism, impaired neuronal signaling may lead to abnormal processing of APP and subsequent A␤ deposition. Consequently, it is important to understand the regulatory mechanism of APP metabolism by neurotransmitter receptors.
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ** Present address: Centro de Investigación del Cá ncer, University of Salamanca-CSIC, 37007 Salamanca, Spain.
‡ ‡ To whom correspondence should be addressed: INSERM U-446, Faculté de Pharmacie, F-92296 Châ tenay-Malabry, France. Tel.: 33 1 46 83 57 18; Fax: 33 1 46 83 54 75; E-mail: Frank.Lezoualch@cep. u-psud.fr. 1 The abbreviations used are: AD, Alzheimer's disease; A␤, amyloid ␤-protein; APP, amyloid precursor protein; sAPP␣, non-amyloidogenic soluble of the amyloid precursor protein; GPCRs, G-protein-coupled receptors; 5-HT, 5-hydroxytryptamine; h5-HT 4 , human 5-HT 4 receptor; GR113808, The serotonin 5-HT 4 receptor has recently gained a lot of attention for its physiological effects in the brain (20) . Indeed, with the recent availability of selective 5-HT 4 ligands, pharmacological studies have shown that activation of the 5-HT 4 receptor increases memory and learning in rats (21) . Accordingly, 5-HT 4 receptor-binding sites have been detected in the hippocampal formation and in neocortical areas (22) , and activation of the 5-HT 4 receptor stimulates acetylcholine release in rat frontal cortex (23) . Moreover, there is a marked loss of 5-HT 4 receptor-binding sites in cortical and hippocampal regions in the brain of AD patients (24) . Altogether these observations suggest that the 5-HT 4 receptor may be a potential pharmacological target for the treatment of AD.
Several splice variants of the human 5-HT 4 receptor (h5-HT 4 ) have recently been described, particularly at the C terminus where alternative splicing results in divergent sequences following Leu 358 (25) (26) (27) (28) . These h5-HT 4 receptor isoforms belong to the family of seven transmembrane domain G-protein-coupled receptors that activate adenylyl cyclase (25) (26) (27) (28) . Most of the h5-HT 4 receptor splice variants are expressed in the brain. Despite a report of beneficial effects of 5-HT 4 ligands on memory in rats (21) , there is no information about the biological significance of the recently cloned h5-HT 4 receptor isoforms in the brain. In this study, we show for the first time that activation of the human 5-HT 4 (h5-HT 4 ) receptor increases the secretion of the non-amyloidogenic sAPP␣. This process is demonstrated in CHO cells stably expressing the h5-HT 4(e) receptor, a neuronal h5-HT 4 receptor isoform, and in IMR32 neuroblastoma cells using 5-HT 4 selective ligands. In addition, we analyzed the signaling pathways involved in sAPP␣ release after activation of the h5-HT 4(e) receptor isoform.
EXPERIMENTAL PROCEDURES
Materials-All media, sera, and antibiotics used in the cell culture were purchased from Life Technologies, Inc. Cell Culture and Transient Transfection-The human neuronal neuroblastoma cell line IMR32 was purchased from ATCC (Manassas, VA) and was grown at 37°C and 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (FCS), 1% non-essential amino acids, and antibiotics. Chinese Hamster ovary cells (CHO) cells stably expressing the h5-HT 4(e) receptor isoform were cultured as described previously (28) . For transient transfection experiments, CHO cells stably expressing the h5-HT 4(e) receptor isoform were transfected with the cDNA encoding the human APP695 using jetPEI TM (Polyplus transfection, Illkirch, France) according to the manufacturer's instructions. Briefly, 50 -60% confluent cell cultures were incubated for 5 h in a mixture of a cationic transfection reagent vector and APP695 cDNA. At the end of the incubation period, media were changed, and cells were cultured for an additional period of 60 h before the determination of sAPP␣ and A␤.
PCR Study-PCRs for the detection of the expression of h5-HT 4 receptor mRNAs in IMR32 cells were performed as described previously (28) . Briefly, total RNA was extracted from IMR32 cells using the Trizol RNA purification system (Life Technologies, Inc.). RNA was then reverse-transcribed with oligo(dT) primers and Superscript reverse transcriptase (Life Technologies Inc.). cDNA specific for the common part of the h5-HT 4 receptor isoforms was detected using a nested PCR amplification. A first reaction was performed using 50 ng of cDNA together with specific primers, C1F (5Ј-TAATGCTGGGAGGCTGCTGG-3Ј) and C1R (5Ј-AGAGGATGATGAGGAAGGCA-3Ј) designed to the 5Ј-and 3Ј-end of the h5-HT 4 receptor, respectively. Products of this first reaction were used as templates for a nested PCR amplification with specific C2F forward primer (5Ј-ATGGTCAACAAGCCCTACGC-3Ј) and C2R reverse primer (5Ј-GCAGAGGCAGAAGCAACCCA-3Ј) that recognize the common part of h5-HT 4 receptors. PCRs were performed as follows: 30 cycles (30 s at 94°C, 45 s at 55°C, and 1.5 min at 72°C) and a final elongation (8 min at 72°C). The PCR products were run on a 1.5% agarose gel and visualized under UV.
Antibodies-R1736 (antibody kindly provided by Dr. Dennis Selkoe, Harvard Medical School, Boston) is a rabbit polyclonal antiserum raised to a synthetic peptide of amino acids 595-611 of APP (29) . This corresponds to positions Ϫ2 to ϩ15 of human A␤, and it presents 90% (15 out of 17 amino acids) of sequence homology with the hamster sequence which is identical to other rodents such as mouse (GenBank TM accession number AF030413). R1736 is not only selective for the human APP␣ but also for the rodent form. Indeed, it has been successfully used to show the endogenous ␣-secreted cleavage of APP molecules with a molecular mass of around 110 kDa in several rodent cellular systems (19, 29) . 22C11 is a monoclonal antibody directed against the N-terminal part of APP (5) (Roche Molecular Biochemicals). Monoclonal antibodies 4G8 and 6E10 (Signet Laboratories, Dedham, MA) are reactive to amino acid residues 17-24 and 1-17 of A␤, respectively (52) .
Measurement of sAPP␣ by Western Blot-For determination of secreted and intracellular sAPP, confluent CHO and IMR32 cell cultures were cultured in 5% dialyzed FCS-containing medium overnight and in serum-free medium for 4 h, respectively. At the beginning of the assay, CHO cells were washed with PBS and preincubated for 15 min in serum-free medium supplemented with 1 M GR127935 to block the activity of endogenous 5-HT 1B receptors. Then 5-HT 4 ligands and drugs were added for the indicated times. Conditioned supernatants containing secreted proteins were collected, and cells were lysed for subsequent analyses.
Collected media were centrifuged to remove cell debris, size-selected using Sephadex G-25M columns (Amersham Pharmacia Biotech), and reconstituted in 70 l of buffer consisting of 50 mM Tris, pH 7.4, 5 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride. The protein amount in each sample was determined with the bicinchoninic acid assay (Sigma). 50 g of cell lysates or 100 g of secreted proteins were run on 8% SDS-polyacrylamide gel and transferred to a polyvinylidene fluoride membrane (Hybond-P, Amersham Pharmacia Biotech). Membranes were blocked by incubation overnight at 4°C with 5% non-fat dry milk in Tris-buffered saline (20 mM Tris, pH 7.6, 137 mM NaCl) containing 0.5% Tween 20 and then were rinsed in Tris-buffered saline containing 0.5% Tween and incubated with the monoclonal antibody 22C11 (5) (1:80 dilution), the polyclonal antiserum R1736 (1:3000 dilution), or the monoclonal antibody 6E10 (1:1000 dilution). After incubation at room temperature for 2 h, blots were rinsed in Tris-buffered saline containing 0.5% Tween and were incubated with a horseradish peroxidase-linked sheep anti-mouse or goat anti-rabbit immunoglobulin antibody (Amersham Pharmacia Biotech) at 1:7500 dilution for 1 h at room temperature. Immunoreactive bands were then visualized by the ECL detection kit (Amersham Pharmacia Biotech) on Kodak ML lights films. For quantification, films of representative experiments were scanned using a Bio-Rad image acquisition system (Ivry-Sur-Seine, France, gel doc 1000) and fold induction of sAPP␣ expression level compared with corresponding controls was calculated. Western blot experiments were repeated at least 3 times with identical results.
Determination of A␤-Secretion media and cell lysates were collected and diluted in a 0.1 volume of TNE buffer 10ϫ (150 mM NaCl, 1 mM EDTA, 10 mM Tris, pH 7.5). Total A␤ was immunoprecipitated overnight with a 200-fold dilution of 4G8 clone in the presence of protein G-Sepharose. Following immunoprecipitation, samples were electrophoresed on 16.5% Tris/Tricine SDS-polyacrylamide gels and transferred onto a 0.2 m nitrocellulose membrane (Schleicher & Schuell) at 380 mA for 45 min. Filters were boiled in phosphate-buffered saline for 5 min and analyzed by Western blot as described above using a 1:1000 dilution of the monoclonal antibody 6E10.
Cyclic AMP Radioimmunoassay-For measurement of intracellular cAMP production, IMR32 neuroblastoma cells grown to confluence in 60-mm plates were incubated overnight in serum-free Dulbecco's modified Eagle's medium. At the beginning of the assay, IMR32 cells were preincubated for 15 min in serum-free medium supplemented with 5 mM theophylline and 10 M pargyline. The 5-HT 4 antagonist, GR113808, was also included during this preincubation period. 5-HT or other serotoninergic agonists were then added for an additional 10-min period. The reaction was stopped by aspiration of the medium and addition of 500 l of ice-cold perchloric acid (20%). After a 30-min period, neutralization buffer was added (25 mM HEPES, 2 N KOH). cAMP was quantified using a radioimmunoassay kit (cAMP competitive radioimmunoassay, Immunotech, Marseille, France).
Protein Kinase A Activity Assay-This assay was performed as described previously (30) . Briefly, CHO cells were grown in 100-mm dishes and then stimulated as described and lysed in a buffer containing 50 mM HEPES, pH 7.6, 150 mM NaCl, 10 mM EDTA, 10 mM NaPP i , 2 mM sodium orthovanadate, 100 mM NaF, 100 IU/ml aprotinin, 5 g/ml leupeptin, and 1% Triton X-100. The lysates were centrifuged at 12,000 ϫ g for 10 min at 4°C and were incubated with the following buffer containing 10 mM HEPES, pH 7.2, 68.5 mM NaCl, 2.7 mM KCl, 0.15 mM KH 2 PO 4 , 0.5 mg/ml glucose, 25 mM ␤-glycerophosphate, pH 7.2, 10 mM MgCl 2 , 1 mM EGTA, 1.85 mM CaCl 2 , 0.1 mM ATP, 100 M Kemptide (Calbiochem) and 20 Ci of [␥-
32 P]ATP (3000 Ci/mmol, PerkinElmer Life Sciences). The reaction was performed at 37°C for 10 min and then stopped by spotting onto Whatman P81 papers. The papers were washed three times with 1% (v/v) orthophosphoric acid, rinsed twice in ethanol, and air-dried. The radioactivity was determined by scintillation counting.
Statistical Analysis-An unpaired Student's t test was used to calculate differences between means; differences were considered significant at p Ͻ 0.05.
RESULTS

5-HT Stimulates the Cellular Release of sAPP␣ in CHO Cells
Stably Expressing the h5-HT 4(e) Receptor-The effect of the activation of the h5-HT 4 receptor on sAPP␣ release was analyzed in CHO cells stably expressing the neuronal h5-HT 4(e) receptor isoform (28) . This CHO cell line stably transfected with the recombinant h5-HT 4(e) receptor displayed a typical 5-HT 4 pharmacological profile as determined previously in binding studies and adenylyl cyclase assays (28) . In addition, the receptor is expressed at physiological density because the number of specific 5-HT 4 -binding sites is in accordance with that found in human brain (28) .
By using an N-terminal monoclonal antibody against APP (22C11) (5, 15), we showed by Western blot that secreted sAPP␣ is increased in CHO cell clones following a 30-min incubation with 1 M 5-HT compared with untreated control cells (Fig. 1) . Because the 22C11 monoclonal antibody can also recognize APP-like proteins such as APP-like protein 2 (31), we performed immunoblots with the R1736 antiserum which is specific for sAPP␣ (29) . Similarly, a single band migrating at the expected molecular mass of 110 kDa was also detected with R1736 ( Fig. 1) . These data suggest that secreted sAPP is produced by non-amyloidogenic ␣-cleavage.
5-HT-induced secretion of sAPP␣ in CHO cells expressing the h5-HT 4(e) receptor was dose-dependent ( Fig. 2A) . Fig. 2A shows a representative gel depicting an increase in sAPP␣ secretion with increasing concentrations of 5-HT after 30 min of application. The levels of secreted sAPP␣ after treatment with micromolar concentrations of 5-HT was significantly different in CHO cells transfected with the h5-HT 4(e) receptor from that of non-transfected cells ( Fig. 2A, lower panel) . The 5-HT-induced increase in sAPP␣ release reached a plateau, and the maximal release of sAPP␣ obtained at 1 M 5-HT was about 2.5-fold (range 2.1-3.7) above its basal level ( Fig. 2A, 
lower panel).
No effect of 5-HT on sAPP␣ release could be detected in the non-transfected CHO control cells ( Fig. 2A,  lower panel ). In addition, the level of intracellular sAPP␣ was also enhanced after 30 min of treatment with increasing concentrations of 5-HT (Fig. 2B) . Time course analyses showed that 5-HT-induced release of sAPP␣ was rapid, and the amount of secreted sAPP␣ reached a plateau with a maximum after 15 min of incubation with 1 M 5-HT in CHO cells expressing the h5-HT 4(e) receptor (Fig. 3) .
Effects of a Selective 5-HT 4 Antagonist, GR113808, on Basal and Stimulated Levels of Secreted sAPP␣ in CHO Cells-Next we examined whether the selective 5-HT 4 antagonist, GR113808, blocked 5-HT-induced sAPP␣ secretion. As shown in Fig. 4 , increasing concentrations of GR113808 antagonized 5-HT-enhanced sAPP␣ release in CHO cells expressing the h5-HT 4(e) receptor. This result indicates that the effects of 5-HT on secreted sAPP␣ is specifically mediated by the h5-HT 4(e) receptor (Fig. 4) . In addition, a constitutive activity of the h5-HT 4(e) receptor on basal sAPP␣ release was observed in the absence of any 5-HT 4 ligand (Fig. 5A) . Indeed, the relative basal level of secreted sAPP␣ in CHO cells stably expressing the h5-HT 4(e) receptor was around 2-fold higher than in untransfected CHO cells (Fig. 5A ). This effect was not due to the presence of 5-HT in culture medium because cells were cultured overnight before the assay in dialyzed FCS-containing medium. These data clearly indicate that expression of the h5-HT 4(e) receptor induced a spontaneously active receptor state that may influence sAPP␣ release.
Because constitutive activation of G-protein-coupled receptors is often related to inverse agonist properties, we tested the effects of the potent 5-HT 4 antagonist, GR113808, on the intrinsic activity of the h5-HT 4(e) receptor (Fig. 5B) . GR113808 (1 M), which behaved as inverse agonist at the h5-HT 4(e) receptor on cAMP production (28), also reduced the constitutive activity of the h5-HT 4(e) receptor on sAPP␣ extracellular release (Fig. 5B) . 4 receptor isoforms are positively coupled to adenylyl cyclase (25-27), and we have recently shown that activation of the h5-HT 4(e) receptor isoform stably expressed in CHO cells strongly enhances cAMP production (28) . To examine the involvement of cAMP in APP metabolism, we treated CHO cells transfected with the h5-HT 4(e) receptor isoform with the adenylyl cyclase activator forskolin (1 M) or the membrane-permeant 8-Bromo-cAMP (10 M) for 15 min. Both drugs mimicked the effects of 5-HT-induced sAPP␣ secretion because they caused a robust increase in secreted sAPP␣ as determined by Western blot using the R1736 antiserum (Fig. 6A) . However, the sAPP␣ secreted form observed in forskolin-and cAMP-treated cells appears to migrate at a lower molecular weight than in the control (Fig. 6A) suggesting that the glycosylation state of secreted sAPP␣ may be influenced by cAMP. Therefore, these results suggest an effect of cAMP on cellular trafficking by increasing full-length APP to compartments involved in ␣-secretase processing. The increases in secreted sAPP␣ was accompanied by an increase in the intracellular level of sAPP␣ (Fig. 6A) .
Analysis of the Signaling Pathways Involved in the h5-HT 4(e) Receptor-induced sAPP␣ Secretion-h5-HT
It is well known that activation of 5-HT 4 receptors induces intracellular production of cAMP that then activates protein kinase A (PKA) (32) . Therefore, to test the role of PKA in 5-HT-induced increase in cellular and secreted sAPP␣, we treated CHO cells stably expressing the 5-HT 4(e) receptor with 10 M of the PKA inhibitor, H89, and measured intracellular and secreted levels of sAPP␣ following 5-HT 4(e) receptor activation (Fig. 6, B and C) . Surprisingly, H89 failed to block the response to 5-HT, but it strongly enhanced basal sAPP␣ and 5-HT-induced sAPP␣ (Fig. 6, B and C) . Indeed, 5-HT (1 M) increased about 2-fold the cellular level of sAPP␣ compared with control untreated cells, whereas the stimulation reached more than 6-fold (range 2-8.5) the control value in the presence of H89 (10 M) (Fig. 6C) . H89 was effective because it completely inhibited 5-HT-enhanced PKA activity in this cellular system (Fig. 6D) . Taken together, these results suggest that PKA exerts a negative regulation on 5-HT-induced increase in secreted and cellular sAPP␣. Because 5-HT 4 receptors activate both cAMP production and PKA, its effect on sAPP␣ regulation must involve a PKA-independent mechanism.
Selective 5-HT 4 Ligands Regulate sAPP␣ Secretion in Human IMR32 Neuroblastoma Cell Line-To test further for the effects of the activation of native h5-HT 4 receptors on sAPP␣ secretion, we used IMR32 cells that express h5-HT 4 receptor transcripts as determined by RT-PCR analysis (data not shown). This cell line also expresses additional neurotransmitter receptors such as the serotonin 5-HT 2C receptor (33) . Therefore, we used the 5-HT 4 agonists, prucalopride and renzapride, to activate selectively the h5-HT 4 receptor, and we determined its effect on sAPP␣ release. As shown in Fig. 7A , 5-HT, prucalopride, and renzapride used at the concentration of 1 M produced an increase in secreted sAPP␣. Among these 5-HT 4 ligands, prucalopride was the most potent agonist in stimulating sAPP␣ (Fig. 7A) . As expected, the selective 5-HT 4 antagonist, GR113808 (1 M), blocked the cellular release of sAPP␣ induced by prucalopride and renzapride. However, it failed to do so with 5-HT, probably because of the presence of other 5-HT receptors such as the 5-HT 2C receptor in this cell line. This 5-HT receptor has also been shown to be involved in APP processing (34) . We then verified whether the strong effect of prucalopride on sAPP␣ release would correlate with its effect on cAMP production. Prucalopride (1 M) induced a robust stimulation of basal cAMP in IMR32 cells, and as expected, it was ineffective in the presence of the prototypic 5-HT 4 antagonist, GR113808 (1 M) (Fig. 7B) .
Effect of 5-HT 4 Receptor Activation on A␤ Production-Many assays are not sensitive enough to detect A␤ peptides in the medium of cells containing low amounts of endogenously expressed APP. CHO cells have been reported to express very low levels of A␤ (51), and most of the antibodies directed against A␤ peptides are selective of humans and do not cross-react at optimal concentration with the rodent forms. For all these reasons, we have transiently transfected the cDNA encoding the human APP695 in CHO cells stably expressing the h5-HT 4(e) receptor isoform, and we determined the effects of 5-HT 4 receptor activation on both secreted APP␣ (sAPP␣) and A␤ peptides. To detect A␤, we set up a sensitive and specific immunoprecipitation/Western blot protocol by employing monoclonal antibodies 4G8 for immunoprecipitation and 6E10 for Western blotting (see "Experimental Procedures"). The antibody 6E10 is specific for the ␣-secretase cleaved form of human APP (52) .
As shown in Fig. 8A , 5-HT enhanced human sAPP␣ secretion in CHO cells transfected with APP695. These results indicate that the activation of the h5-HT 4(e) receptor not only stimulates the release of endogenous sAPP␣ but also the human form in CHO cells. To elucidate whether the stimulating effect of the 5-HT 4 receptor affects A␤ generation, A␤ (1-40 and 1-42) was immunoprecipitated from the corresponding CHO cell culture media (Fig. 8B) . In fact, we did not observe any effect of 5-HT (1 M) on A␤ production compared with untreated control CHO cells (Fig. 8) . We also assessed whether intracellular A␤ was affected by 5-HT cell treatment. Although our immunoprecipitation/Western blot protocol can readily detect as little as 500 pg of synthetic human A␤, we were not able to detect any clear band representative of intracellular A␤ in CHO cell lysates transiently transfected with APP695 under this experimental condition (data not shown). This finding is in accordance with the fact that A␤ is more abundant in the extracellular medium than in cell lysates (53) . DISCUSSION In this study, we have examined the effects of 5-HT 4 ligands on intra-and extracellular levels of sAPP␣. We employed two cellular systems as follows: a CHO cell line stably expressing physiological density of the h5-HT 4(e) receptor isoform (28) , and a human neuroblastoma cell line, IMR32, that expresses native 5-HT 4 receptors. In CHO cell clones, we showed that 5-HT enhanced the level of extracellular sAPP␣ in a time-and dosedependent manner. The increase in cellular release of sAPP␣ was detected within 15 min following application of 5-HT, suggesting that it derives from a pool of pre-existing intracellular proteins and not from newly synthesized APP proteins. Furthermore, 5-HT-induced sAPP␣ secretion was blocked by a selective 5-HT 4 antagonist, GR113808. Hence, we showed that 5-HT 4 agonists enhanced release of secreted sAPP␣ in neuroblastoma IMR32 cells. Increased APP secretion was detected by a non-selective monoclonal antibody as well as by the R1736 antiserum that recognizes ␣-secretase-cleaved APP (29) . Altogether, these data indicate that 5-HT and 5-HT 4 ligands increase the cellular release of sAPP␣ through their specific interaction with the h5-HT 4 receptor. To the best of our knowledge, this is the first report showing a specific cellular function for the recently cloned h5-HT 4(e) receptor.
Recently, evidence has been provided that members of the ADAM family act as ␣-secretases. ␣-Cleavage of APP can occur at multiple locations within the cell as has been shown for PKC-induced sAPP␣ secretion (58) . In our study, the cellular mechanism by which the activation of the h5-HT 4(e) receptor results in the secretion of sAPP␣ may not be directly linked to an increase in the activity of the ␣-secretases but could also reflect an effect on cellular trafficking of APP. Indeed, one could imagine that activation of the 5-HT 4(e) receptor causes an increase in the trafficking of APP to cellular compartments involved in ␣-secretase processing. This is supported by the results of Fig. 6 showing that the intracellular pool of sAPP␣ in cells stimulated with cAMP is migrating faster than that of the control. This possibly indicates an effect of this second messenger on the glycosylation state of secreted sAPP␣.
Non-amyloidogenic secreted sAPP␣ has potent neuroprotective functions against excitotoxic and oxidative insults in various cellular models (6, 7) , and it was shown recently (35) to confer resistance against p53-mediated apoptosis. In addition, sAPP␣ promotes neurite outgrowth and regulates neuronal excitability (36) . Intracerebroventricular administration of secreted forms of sAPP␣ to amnestic mice has potent memoryenhancing effects and blocks learning deficits induced by scopolamine (37) . This observation together with our reported data (21) GPCRs (16) . For instance, muscarinic m1 and m3 receptor activation results in the activation of phospholipase C leading to a rise in intracellular calcium, diacylglycerol, and inositol triphosphate that parallels sAPP␣ secretion. The stimulation of metabotropic glutamate receptors was also shown to increase the release of sAPP␣ (17, 38) . The effects of phospholipase C-coupled receptors on sAPP␣ secretion are thought to be mediated mainly by PKC that has also been shown to decrease A␤ production in various cell lines (39) . Serotonin 5-HT 4 receptors are positively coupled to adenylate cyclase, and consequently they increase cAMP production (26, 28, 40) . In our study, forskolin and 8-bromo-cAMP mimicked the stimulation of sAPP␣ by 5-HT in CHO cells. These findings agree with previous observations (19, 41) showing that cAMP and seven transmembrane receptors that are coupled to the heterotrimeric G s protein may increase sAPP␣. However, in C6 cells transfected with the full-length APP751, forskolin and the cAMP analogue, dibutyryl cAMP, inhibited both the constitutive and phorbol ester-stimulated secretion of sAPP␣ (42) . In astrocytes, both drugs also inhibited the increase in sAPP␣ secretion caused by phorbol ester but did not affect basal sAPP␣ levels (43) . Although further experiments are needed to solve this discrepancy, it is conceivable that the balance between the PKA-dependent inhibitory and the PKA-independent stimulatory mechanisms may differ in different cell types.
Interestingly, a constitutive activation on secreted sAPP␣ was found with the h5-HT 4(e) receptor stably expressed in CHO cells. Constitutive coupling to cAMP was already described for the h5-HT 4(e) receptor and other 5-HT 4 receptor splice variants such as the h5-HT 4(d) receptor (40) . In addition, we found that GR113808 decreased basal secreted levels of sAPP␣ indicating that this selective 5-HT 4 antagonist behaves as an inverse agonist. This confirms our previous finding (28) that GR113808 reduces the basal cAMP production in CHO cells transfected with the 5-HT 4(e) receptor. At present, the physiological relevance of inverse agonism is not clear. Inverse agonistic properties are suggested to be of therapeutic relevance in the treatment of disorders related to constitutive receptor activation. Our results suggest that inverse agonists, through their action on GPCRs signaling, may also influence the processing of molecules having important physiological functions such as APP.
Activation of PKA usually results from an increased production of cAMP via G s protein-coupled receptor. Activation of the recombinant h5-HT 4(e) receptor isoform in CHO cells as well as that of the native h5-HT 4 in IMR32 neuroblastoma cells was accompanied by a net increase in the level of intracellular cAMP. Classically, cAMP mediates its action by activation of PKA and phosphorylation of substrate proteins. Surprisingly, the PKA inhibitor H89 strongly boosted the stimulatory effect of 5-HT on intra-and extracellular levels of sAPP␣ in CHO cells stably expressing the 5-HT 4(e) receptor isoform. We also found that H89 increased the constitutive expression of sAPP␣. This observation agrees with the previous study of Marambaud et al. (44) who showed that PKA inhibitors selectively lower A␤ production in human embryonic kidney 293 cells expressing wild type or mutated APP. However, these authors did not observe any effect of H89 on the basal constitutive release of sAPP␣.
Our results show that the effect of the activation of the h5-HT 4 receptor on sAPP␣ secretion involves cAMP production and a novel PKA-independent stimulatory process that overcomes a PKA-dependent inhibitory one. In most cellular systems, cAMP effects have been considered to be the result of PKA activation. However, PKA-independent signaling pathway has been reported for some ion channels such as the pacemaker channel (45, 46) . In addition, several guanine nucleotide exchange factors that regulate the activity of small GTP-binding proteins can also be directly activated by cAMP (47, 48) . The functions of specific small G-proteins are not fully understood, and it will be interesting to determine whether they are involved in sAPP␣ secretion. Finally, to explain the inhibitory effect of PKA on 5-HT-induced intracellular and extracellular content of sAPP␣, one could speculate that the 5-HT 4(e) receptor isoform is coupled to an additional signal transduction cascade that could influence sAPP␣ secretion. It is now well accepted that one GPCR is capable of interacting with more than one G-protein to result in multifunctional signaling (49) . This is illustrated by the work of Namba et al. (50) who have shown that the isoforms of the prostaglandin EP3 receptor, which differ only at their C-terminal tails and are produced by alternative splicing, couple to different G-proteins to activate different messenger systems.
In contrast to sAPP␣, we were unable to detect any change in secreted A␤ levels upon stimulation of the 5-HT 4(e) receptor in CHO cells transfected with the human APP695. Our data contrast with several reports showing reduced A␤ formation under conditions of enhanced sAPP␣ secretion (for review see Ref. 16 ). For instance, in cells overexpressing APP, cholesterol depletion-induced sAPP␣ secretion is accompanied by a decrease of A␤ production (54) . However, other studies failed to demonstrate any association between sAPP␣ secretion and A␤ generation both in vivo and in vitro (55) . Rossner et al. (56) showed that constitutive activation of PKC in guinea pig brain increased sAPP␣ secretion without any effect on secreted A␤ suggesting that the ␣-and ␤-secretase pathways may be differentially controlled. Their conclusion is supported by the different cellular sites of sAPP␣ and A␤ generation. In neurons, A␤-(1-42) and A␤-(1-40) are produced in the endoplasmic reticulum and in the trans-Golgi network, respectively (for review see Ref.
2). In our experimental conditions, we detected total extracellular A␤, and therefore we cannot exclude that 5-HT may differentially influence A␤-(1-42) and A␤- levels. This hypothesis is currently under our investigation using selective antibodies against each peptide. Also, intracellular and extracellular A␤ peptides may be differentially regulated as has been shown recently for the growth factor insulin (57) . Stable CHO cell lines co-expressing the h5-HT 4 receptor and APP695 should allow us to address this question.
In conclusion, in the present study, we provide the molecular basis of the involvement of the h5-HT 4 receptor in the regulation of sAPP␣ secretion. Our results show that selective 5-HT 4 agonists increase non-amyloidogenic secreted sAPP␣ in nonneuronal and neuronal cells. Given the neuroprotective activity and memory-enhancing effects of sAPP␣, 5-HT 4 receptors could constitute a potential novel pharmacological target for the treatment of AD.
